Table 3.
Effect of amphotericin B formulations on hepatic and renal parameters.
| Amphotericin B Formulations | Dose (mg/kg) | ALTa (IU/L) | ASTa (IU/L) | BUNa (mmol/L) | Creatinine (μmol/L) |
|---|---|---|---|---|---|
| Controlb | 0 | 149.8 ± 14.8 | 18.0 ± 2.0 | 5.4 ± 2.6 | 35.5 ± 1.02 |
| AmB-NA3 | 1 | 148.3 ± 22.8 | 19.3 ± 1.9 | 5.8 ± 0.3 | 37.5 ± 0.06 |
| 5 | 161.2 ± 8.4 | 17.3 ± 1.7 | 6.2 ± 1.9 | 39.3 ± 1.71 | |
| 10 | 154.0 ± 29.4 | 20.6 ± 7.0 | 5.5 ± 2.6 | 42.5 ± 1.00 | |
| 15 | 350.0 ± 2.4* | 31.8 ± 5.7* | 8.8 ± 2.3* | 58.5 ± 1.49* | |
| AmB-NA5 | 1 | 146.3 ± 2.8 | 17.3 ± 1.1 | 5.8 ± 1.3 | 39.5 ± 1.60 |
| 5 | 162.8 ± 19.2 | 18.8 ± 4.5 | 6.0 ± 1.2 | 36.6 ± 1.52 | |
| 10 | 167.1 ± 8.4 | 19.3 ± 2.7 | 6.2 ± 1.9 | 40.0 ± 1.87 | |
| 15 | 335.0 ± 8.4* | 27.8 ± 2.4* | 8.3 ± 1.3* | 56.5 ± 1.91* | |
| Fungizone | 2 | 704.0 ± 27.6* | 49.0 ± 2.2* | 16.2 ± 0.2* | 88.7 ± 2.22* |
| AmBisome | 10 | 205.2 ± 14.3* | 24.8 ± 3.8* | 5.7 ± 1.0 | 46.3 ± 3.14 |
The two commercial formulations of Amphotericin B, Fungizone and AmBisome, were used at dose of 2 and 10 mg/kg, respectively.The new formulations (AmB-NA3 and AmB-NA5) were used in a range of concentrations (1–15 mg/kg). Values are mean ± SD.
*Significant at P < 0.05compared with the results for the respective control mice, Student’s t test.
aALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.
bControl mice were given only PBS.